Note: Descriptions are shown in the official language in which they were submitted.
CA 02384504 2008-07-16
Use of Retigabin for Treating Neuropathic Pain
The invention relates to the use of 2-amino-
4-(4-fluorobenzylamino)-1-ethoxycarbonylaminobenzene of
the formula-I
NH 0
NH ~
F aNH
2 ~
(INN: retigabine)
or its pharmaceutically utilizable salts for the
prophylaxis and treatment of neuropathic pain.
Neuropathic pairi such as allodynia and hyperalgesia
describes a particular type of pain sensation which
differs from the customary perception of painful
stimuli. Patients who suffer from hyperalgesic. pain
feel painful stimuli more strongly than healthy people.
The term allodynia describes the phenomenon of the
perception of stimuli which are not painful per se,
such as contact or heat/cold, as pain. In some cases,
the perceptions felt are very strong and stressful.
This modified pain sensation is covered in German and
International usage by various terms -which in some
cases overlap in their meaning but cannot always be
used synonymously. In German usage, the -terms
Allodynie, Parasthesie, Hyperesthesie, Hyperalgesie and
Phantomschmerz (allodynia, paraesthesia, hyperaesthesia
hyperalgesia and phantom pain) are customary, in
English usage, in addition to allodynia; hyperalgesia
and phantom limb pain, the terms reflex sympathetic
dystrophy (RSD) (Rogers and Valley, 1994) and
sympathetically maintained pain (SMP) are furthermore
used (Rogers JN;. Valley MA, Reflex sympathetic
dystrophy; Clin Podiatr Med Surg.. 1994 Jan.; 11(1): 73-
83).
^
CA 02384504 2002-03-26
- 2 -
Allodynia is understood as meaning the intensified
unpleasant to painful perception of stimuli triggered
by heat or by contact, which is based on a lowering of
the pain threshold for these stimuli only. Hyperalgesia
describes the excessive perception of stimuli of all
sorts which are painful per se, again on account of a
lowering of the pain threshold. Phantom pain is
designated as the perception of pain which is
non-existent, since, for example, the painful. extremity
has been amputated. In the scientific literature, this
type of pain sensation is often subsumed under the term
centrally mediated neuropathic pain. It is
characteristic here that the actual pain sensation is
not be attributed to a customary pain-inducing
stimulus, but'is generated by the peripheral or central
nervous system, as the level of reaction of the pain-
sensing and pain-transmitting system is altered. Unlike
other forms of pain, neuropathic pain is usually
chronic and customarily cannot be treated or can only
be treated with difficulty with conventional analgesics
such as opioids.
Disorders in which a modified level of reaction of the
pain-sensing and pain-transmitting system is observed
can be:
1. Long-lasting allodynia is described as a classical
result of the herpes zoster (shingles) infection
(Fields et al., 1998; Fields HL; Rowbotham M;
Barons R, Posttherapeutic neuralgia: irritable
nociceptors and deafferentation. Neurobiol. Dis.
1998 Oct.; 5(4): 209-27).
2. In the case of AIDS patients, in various stages of
the disorder pain sensations occur which belong to
the hyperalgesia type and are clearly to be
differentiated from nociceptive (i.e. induced by
painful stimuli) pain (Lefkowitz 1996;
CA 02384504 2002-03-26
- 3 -
Lefkowitz M, Pain management for the AIDS patient.
J Fla Med. Assoc. 1996 Dec.; 83(10):701-4).
3. In the parts of the body affected, burn wounds
lead to neuropathic hyperalgesias. Although the
pain-inducing cause (heat) is no longer present,
burn wounds are often extremely painful.
4. After therapy with high doses of cytostatics for
cancer treatment, patients often also report pain
sensations (Brant 1998; Brant JM, Cancer-related
neuropathic pain. Nurse Pract. Forum. 1998 Sep.;
9(3): 154-62). Tanner et al. (Tanner KD; Reichling
DB; Levine JD, Nociceptor hyper-responsiveness
during vincristine-induced painful peripheral
neuropathy in the rat. J. Neurosci. 1998 Aug. 15;
18(16): 6480-91) were able to show that pain which
occurs in connection with vincristine treatment is
caused by an increased stimulability of the
peripheral pain receptors, that is by
hyperalgesia.
5. A tumour disorder itself can also elicit
neuropathic pain (e.g. as a result of chronic
nerve compression by the tumour) which belongs to
the hyperalgesia type (Brant 1998; Brant JM,
Cancer-related neuropathic pain. Nurse Pract.
Forum, 1998 Sep.; 9(3): 154-62).
6. Trigeminal neuralgia is a widespread form of
hyperalgesia which often occurs without visible
damage to the nerves (Burchiel, 1993; Burchiel KJ,
Trigeminal neuropathic pain. Acta Neurochir.
Suppl. Wien. 1993; 58; 145-9).
7. In diabetes patients, hyperalgesia often occurs in
the course of the disorder as a form of late
damage. The patients complain about highly painful
limbs with simultaneously reduced contact
^
CA 02384504 2002-03-26
- 4 -
sensitivity of the skin (Bell 1991; Bell DS: Lower
limb problems in diabetic patients. What are the
causes? What are the remedies? Postgrad. Med. 1991
June; 89(8): 237-40, 234-4).
8. The diffuse pain occurring in fibromyalgia is
subsumed under the term allodynia (Russel, 1998;
Russell IJ, Advances in fibromyalgia: possible
role for central neurochemicals. Am. J. Med. Sci.
1998 June; 315(6): 377-84).
9. A further syndrome in which symptoms of
hyperalgesia and allodynia occur is vulvodynia.
This disorder is characterized by chronic malaise
(burning, stabbing, itching) in the region of the
vulva without it being possible to demonstrate
that infective agents are the cause (Bohl et al.,
1998; Bohl TG, Vulvodynia and its differential
diagnoses. Semin. Cutan. Med. Surg. 1998 Sep.;
17(3): 189-95).
10. In patients with chronic back pain, a compression
of nerve roots of the spinal cord can often be
observed. Apart from in chronic pain, this
pressure damage to the nerve roots is also
manifested in sensory malaises (paraesthesias). If
the restriction is eliminated surgically, in spite
of this a large proportion of the patients
additionally complain about pain sensations. These
persistent sensations are described as neuropathic
pain and can be delimited diagnostically from
other (inflammatory) forms of pain (Sorensen and
Bengtsson, 1997; Sorensen J; Bengtsson M,
Intravenous phentolamine test - an aid in the
evaluation of patients with persistent pain after
low-back surgery? Acta Anaesthesiol. Scand. 1997
May; 41 (5) : 581-5).
^
CA 02384504 2002-03-26
- 5 -
11. In 10 to 20% of patients with spinal cord
injuries, in some cases very severe pain
sensations result which are generated in the brain
for lack of intact spinal cord and are not to be
related to a painful stimulus. This pain is
described as central neuropathic pain (Eide 1998;
Eide PK, Pathophysiological mechanisms of central
neuropathic pain after spinal cord injury. Spinal
cord. 1998 Sep.; 36(9): 601-12).
12. Pain occurring after amputations has
characteristics of neuropathic pain (Hill 1999;
Hill A, Phantom limb pain: a review of the
literature on attributes and potential mechanisms.
J. Pain Symptom Manage. 1999 Feb.; 17(2): 125-42).
13. Internal organs can also be a source of
hyperalgesia (Mayer and Gephart, 1994; Mayer EA;
Gebart G, Basic and clinical aspects of visceral
hyperalgesia [see comments in; Gastroenterology
1995 Feb.; 180(2): 618] Gastroenterology. 1994
July; 107(1): 271-93). Affected patients suffer
from inappropriate sensations of physiological
reactions in various regions of the
gastrointestinal tract, such as, for example,
sensation of fullness, stomach pain or the
sensation of flatulence, without appropriate
pathological causes being present.
As mentioned at the outset, an increased or modified
pain reaction is a symptom of various disorders and it
appears questionable whether a standard pathogenesis is
present. This is also seen in the fact that the nature
of the modified pain reaction can be very different. It
is common to all these pain reactions, however, that
morphines are either inactive or only act when using
doses which cause undesired side effects. Triggering
factors for the pain reaction can be varied.
CA 02384504 2002-03-26
- 6 -
In patients with herpes-induced allodynia a draught can
be sufficient in order to cause a burning pain. In
these patients, it is to be assumed that the causative
agents produce damage in neurons, which lowers the pain
threshold. In patients with diabetes, it is suspected
that the low supply of the nerves with blood and
nutrients on account of the microangiopathy leads to
chronic nerve damage. This in turn triggers a
regeneration process which is manifested in
proliferation of nerve fibres.
Reorganization processes in the spinal cord and also
peripherally are regarded as a possible cause of
hyperalgesias by various authors (see, for example,
Basbaum 1999; Basbaum AI, Spinal mechanisms of acute
and persistent pain. Reg. Anesth. Pain Med. 1999
Jan.-Feb.; 24(1): 59-67). As a result of chronic
compression of nerves, these are damaged without being
completely destroyed. While as a result of acute
compression local pain signals are triggered, in
chronic compression an induction of transcription
factors occurs in the cell body (and thus outside the
region of the compression in the bone marrow), which
lasts for weeks. The neuropeptides such as substance P
activate the proliferation of nerve fibres and the
activation of unaffected adjacent neurons. Moreover, it
was possible to demonstrate that the nerve cell bodies
express noradrenaline receptors to an increased extent.
As a result, the neurons can become active
spontaneously without external initiation and
spontaneously trigger pain sensations.
After external stimulation, whole discharge volleys are
transmitted to the brain instead of individual impulses
(Herdegen and Zimmermann, 1995; Herdegen T;
Zimmermann M: Immediate early genes (IEGs) encoding
inducible transcription factors (ITFs) and
neuropeptides in the nervous system: functional
networks for long-term plasticity and pain. In:
Nyberg F; Sharma HS; Weisenfeld-Hallin Z (Eds.):
CA 02384504 2002-03-26
- 7 -
Neuropeptides in the spinal cord. Progress in Brain
Research Vol. 104 Elsevier Publishers, Amsterdam 1995,
pp. 299-321).
On account of the participation of noradrenaline
receptors, the transmitter substance of the sympathetic
system, reference is also made to sympathetically
maintained pain, since theses neurons are activated by
physiological activation of the sympathetic system. In
English usage, the term reflex sympathetic dystrophy
(RSD) is therefore widespread (Rogers and Valley, 1994;
Rogers JN; Valley MA, Reflex sympathetic dystrophy;
Clin. Podiatr. Med. Surg. 1994 Jan; 11(1): 73-83) or
sympathetically maintained pain (SMP).
Cytostatics such as vincristine lead directly to an
increase in the excitability of peripheral pain
receptors and in this way ought to induce hyperalgesia
(Tanner et al. 1998; Tanner KD; Reichling DB;
Levine JD, Nociceptor hyper-responsiveness during
vincristine-induced painful peripheral neuropathy in
the rat. J. Neurosci. 1998 Aug 15; 18(16); 6480-91).
It has been attempted in animal experiments to
elucidate fundamental common mechanisms of
hyperalgesia. If, in rats, a peripherally detectable
severe hyperalgesia is induced by partial ligature of a
nerve branching off from the spinal cord, then
superactive groups of neurons are to be found in the
spinal cord as ectopically spontaneously active foci
(Pan et al., 1999; Pan HL; Eisenach JC; Chen SR,
Gabapentine suppresses ectopic nerve discharges and
reverses allodynia in neuropathic rats. J Pharmacol Exp
Ther. 1999 Mar.; 288(3): 1026-30). By means of
gabapentine, a medicament having a marked action in
neuropathic pain, the spontaneous activity of these
nerve cell foci (ectopic foci) can be suppressed in a
dose-dependent manner. In the same dose range,
peripheral hyperalgesia is also suppressed. Similar
experiments were also carried out in another model
^
CA 02384504 2002-03-26
- 8 -
(Habler et al., 1998; Habler HJ; Liu XG;
Eschenfelder S; Janig W. Is sympathetic-sensory
coupling in L5 spinal nerve-injured rats direct? Soc.
Neurosci. Abstr. 24, 2084). If the spinal nerve L5 was
severed, then unexpectedly it was possible to derive
spontaneous activity of individual nerve fibres from
the nerve stump beginning from day 4 for several weeks.
This phenomenon is possibly to be related to phantom
pain. Possibly, the spontaneous activity of these nerve
fibres after amputation is to be attributed to a
disinhibition of the NMDA subtype of the glutamate
receptor (Zhuo, 1998; Zhuo M, NMDA receptor-dependent
long term hyperalgesia after tail amputation in mice.
Eur. J. Pharmacol. 1998 May 22; 349(2-3): 211-20).
Investigations in which it was possible to show that
intrathecal administration of NMDA antagonists were
able to reduce the pain also point to the involvement
of the NMDA receptor. In summary, it can be established
that overstimulation conditions of the involved nerves
can play a role as a cause of the hyperalgesia or of
the modified pain sensation, but the influence of
further factors is probable.
In the therapy of these disorders, a completely clear
differentiation must be made between the symptomatic
treatment of the pain sensation and the nerve cell-
protecting treatment of the causes of the disorder
(Morz 1999, Mbrz R; Schmerzbehandlung bei diabetischen
Neuropathien (Pain treatment in diabetic neuropathies),
Fortschritte der Medizin 1999, 13: 29-30).
In patients with diabetes-related neuropathic pain, the
optimization of the metabolic levels to avoid further
progression and the prevention of subsequent damage
such as foot lesions is indicated as a basic programme,
but this treatment has no effect on the pain symptoms
per se.
Furthermore, the cause of the disorder, i.e. the
neurodegenerative nerve damage and the underlying
^
CA 02384504 2002-03-26
- 9 -
microangiopathy can be treated by the use of nerve
cell-protecting (neuroprotective) substances such as
alpha-lipoic acid or other antioxidants such as
vitamin E, vitamins relevant to the nervous system,
such as vit. B1, B6 or B12 or by measures improving the
circulation, such as physical exercise.
This type of treatment does not acutely influence the
pain; if, however, an improvement in the nerve function
is achieved, it is possible for the pain sensations to
subside in the long term.
The actual symptomatic pain therapy, however, must
resort to other medicaments. Neither centrally active
analgesics such as morphine derivatives nor customary
peripherally active analgesics such as paracetamol or
acetylsalicylic acid are effective. However,
antidepressants such as amitriptyline, imipramine or
paroxetine or anticonvulsants such as carbamazepine or
gabapentine are employed. Tramadol, as an opioid
analgesic, is also effective on account of its further
actions on other receptors of the adrenergic system.
In the patent literature, for example, the use of
topiramate (US 5 760 007) and moxonidine (EP 901 790)
for the treatment of neuropathic pain is demonstrated.
The aim here is to treat the pain symptoms per se and
not the causes. All medicaments mentioned, however,
only lead to an alleviation of the pain symptoms in
some of the patients.
In herpes-induced neuropathic pain, it is possible
prophylatically by the use of virostatics to protect
the nerve cell causally from the harmful action of the
virus at an early point in time of the disorder and
thereby to reduce the expression of the neuropathic
pain; these medicaments, however, are not effective
symptomatically after the acute infection subsides.
Affected patients can experience alleviation of the
^
CA 02384504 2002-03-26
- 10 -
symptoms by taking antidepressants, carbamazepine or
gabapentine.
In compression-related neuropathic pain, it is possible
to eliminate the primary cause of the disorder, for
example, in the carpal tunnel syndrome or on
compression of spinal cord roots by surgical widening
of the narrow sites. On early administration,
medicaments having a neuroprotective action can delay
or stop the progression of the damage to the nerves. In
spite of this, a high proportion of these patients
still suffer from pain, which, in turn, does not
respond well to classical analgesics, even a long time
after the operation. Antidepressants and medicaments
such as carbamazepine or gabapentine are used.
In the case of amputation pain, the actual cause, the
amputation, cannot be treated, so that neuropathic pain
has to be treated only symptomatically with the
abovementioned groups of medicaments. However, it has
been attempted recently in the case of systematic
amputations to counteract the development of
neuropathic pain by conduction blockade of the nerves
to be severed for several days before carrying out the
amputation. Although the first indications are
positive, the clear demonstration of efficacy in
controlled clinical studies has still not been
furnished.
In summary, it can be established that for the
symptomatic treatment of neuropathic pain conventional
analgesics have a low efficacy. Medicaments such as
antidepressants, carbamazepine or valproate are used,
which per se have no analgesic action on non-
neuropathic forms of pain.
The treatment of these patients, however, is often not
satisfactory.
a
CA 02384504 2002-03-26
- 11 -
There is therefore a great need for novel substances
for the selective treatment of neuropathic forms of
pain.
The aim of this invention is to make available a
substance with which the pain symptoms of neuropathic
pain can be treated.
Surprisingly, it has now been found that retigabine of
the formula I
NH cr -
has NH F significant activities against neuropathic pain.
Thus entirely new possibilities for the prophylaxis and
treatment of neuropathic pain open up.
Retigabine and processes for its preparation have been
disclosed (DE 42 00 259).
Retigabine is a derivative of the non-opioid analgesic
flupirtine, for which an anticonvulsive action was also
demonstrated in addition to its analgesic action. By
means of structural optimization with the aim of better
separation of desired (anticonvulsant) properties from
undesired (analgesic) actions, it was possible using
pharmacophore modelling to separate the anticonvulsant
from the analgesic action in this substance class.
Retigabine has a stronger anticonvulsant action than
flupirtine, but an analgesic action in models of acute
pain is no longer detectable (Rostock et al., 1996;
Rostock A; Tober C; Rundfeldt C; Bartsch R; Engel J;
Polymeropoulus EE; Kutscher B; Loscher W; Honack D:
White HS; Wolf HH, D-23129: a new anticonvulsant with a
broad spectrum activity in animal models of epileptic
seizures. Epilepsy Res. 1996 Apr.; 23(3): 211-23).
^
CA 02384504 2002-03-26
- 12 -
Retigabine has a broad spectrum of action in
experimental models of epileptic attacks (Rostock et
al., 1996; Tober et al., 1996; Tober C; Rostock A;
Rundfeldt C; Bartsch R, D-23129: a potent
anticonvulsant in the amygdala kindling model of
complex partial seizures. Eur. J. Pharmacol. 1996 May
15; 303(3): 163-9) and is in clinical development for
the treatment of epilepsy.
In addition, the use of retigabine for the treatment of
neurodegenerative disorders is described in EP 857 065.
Unexpectedly, we were able to establish that retigabine
has marked dose-dependent action against neuropathic
pain. As expected, however, the analgesic action, as is
seen in this model in the early phase, was only low and
comparable with the reference substance gabapentine.
Pharmacological investigations
Investigation of the inhibition of hyperalgesia in the
rat formalin model
In this model, a biphasic nocifensive behaviour
reaction is induced by the subcutaneous injection of
low-percentage formalin (Field et al. 1997; Field MJ;
Oles RJ; Lewis AS; McCleary S; Hughes J; Singh L;
Gabapentine (neurontin) and S-(+)-3-isobutylgaba
represent a novel class of selective antihyperalgesic
agents. Br. J. Pharmacol. 1997 Aug; 121(8): 1513-22).
The early phase up to at the latest the 10th minute is
characterized by intensive licking and biting. The late
tonic phase occurs 20-60 min after the injection as the
hyperalgesic process stage. The formalin-induced
hyperalgesia includes central mechanisms via
sensitization of the neurons in the dorsal horn of the
spinal cord, which results as a consequence of the
tissue damage or increasing activation of the C-
afferent fibres.
a
CA 02384504 2002-03-26
- 13 -
Field et al. (1997) were able to demonstrate that
opioids are inactive in this model against the late
phase of hyperalgesic behaviour reactions. On the other
hand, the anticonvulsant gabapentine reduced the pain
reactions of the rats in a dose-dependent manner.
Investigations with retigabine
Method:
Male Sprague Dawley rats 70-90 g in weight were adapted
individually and observed for at least 15 min before
the start of the experiment. 0.05 ml of 2.5%
formaldehyde in isotonic saline solution given by
plantar subcutaneous injection in the hind paw brought
about a severe immediate reaction with biting and
licking of a few minutes duration with a subsequent
hyperalgesic late phase for up to 60 rnin after the
injection of formalin. The biting and licking reactions
of the late phase (starting from 10 min) form the
measure of the hyperalgesic reactions. These reactions
are recorded at 5-minute intervals over the course of
40 min. The test substances were administered orally
60 min before the injection of formalin. The reference
substance was gabapentine. 15 animals were employed per
group.
Results:
Retigabine inhibited the late phase of the pain
reactions, to be described as hyperalgesia or
neuropathic pain, in a dose-dependent manner after 5,
10 and 20 mg/kg orally. The action of 10 mg/kg of
retigabine corresponded approximately to the effect of
60 mg/kg of oral gabapentine (see Table 1).
As with gabapentine, the action on the early phase of
the pain, i.e. the analgesic action, was only slight.
Thus, the summed pain reactions in the control group in
the early phase achieved a behaviour score of up to 35
and in the late phase of up to 30. By means of
^
CA 02384504 2002-03-26
- 14 -
retigabine, the pain reaction in the early phase was
reduced in a dose-dependent manner to 32, 25 and 18,
whereas in the late phase almost no pain reaction was
any longer detectable with behaviour scores of in some
cases below 5.
The pain reaction in the early phase was also lowered
only to 27 by gabapentine, whereas in the late phase
values of below 6 were also achieved.
CA 02384504 2002-03-26
- 15 -
Table 1
Effect of retigabine on the hyperalgesia of rats after
oral administration
Treatment Dose Sum of the behaviour score over 5 min averaged starting
mg/kg from formalin administration (average value standard
deviation)
Time 5 10 15 20 25 30 35 40
1 Vehicle - 35.3 14.9 24.0 30.1 28.9 23.9 23.8 17.5
2.76 7.00 7.78 3.91 7.08 7.90 7.61 11.40
2 Retigabine 5.0 31.9 5.33** 9.9** 26.4 21.1 20.6 14.5* 10.9
5.46 6.43 8.51 6.63 6.15 7.85 7.80 t8.98
3 Retigabine 10.0 25.1** 2.5** 5.6** 12.9** 16.5" 8.8- 8.4** 8.3*
6.42 2.78 3.46 8.49 10.49 8.91. t8.47 7.29
4 Retigabine 20.0 17.6- 0.9*` 5:4** 12.5** 9.3*' 9.0** 7.9** 2.9**
8.52 1.81 t8.47 8.83 9.18 8.70 5.91 3.36
5 Gabapentine 60.0 26.5" 4.6" 4.5" 12.4" 11.5" 8.4" 6.8`1 5.6'
6.12 4.53 5.76 7.11 7.27 7.76 8.76 9.21
Statistical differences in comparison to the vehicle-
treated group were carried out for retigabine by means
of variance analysis using the following Williams test
('p<0.05, "p<0.01)
Statistical differences in comparison with the vehicle-
treated group were carried for retigabine by means of
Student's t test (+p<0.05, ++p<0.01)-
f
CA 02384504 2002-03-26
- 16 -
Retigabine of the formula I can be converted in a known
manner into pharmaceutical formulations such as
tablets, capsules, coated tablets, pills, granules,
syrups, emulsions, suspensions and solutions, if
appropriate using pharmaceutically suitable vehicles
and/or excipients.
In the case of oral or parenteral administration, the
daily dose of the compound of the formula I should be
50-500 mg.
Preferably, individual doses of 30-60 mg are
administered in the case of oral administration and 5-
mg in the case of parenteral administration (the
amounts are in each case based on the free base).
15 If necessary, it is possible to depart from the amounts
mentioned, namely depending on the body weight and the
specific type of administration route.
